Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Biogen Idec | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Biogen Idec

In-market Tysabri sales up 23% in 2011

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Biogen Idec

4Q Revenues: $1.3 billion (+9%)

4Q Earnings: $300.2 million (+10%)

FY Revenues: $5.0 billion (+7%)

FY Earnings: $1.3 billion (+41%)

Comments: Tysabri revenues increased 11% in the quarter to $269 million. Global in-market sales were $380 million, up 14%. Avonex revenues were up 8% in the quarter to $703 million. Rituxan revenues from the company’s joint business arrangement were flat at $258 million in the quarter. For the year Tysabri revenues were up 20% to $1.1 billion with global in-market sales of $1.5 billion, up 23%. Avonex revenues were up 7% for the year to $2.7 billion. Rituxan sales were $1.0 billion for the year, down 7% due certain royalties from individual countries expiring and a charge of approximately $50 million related to Genentech’s arbitration with Hoechst GmbH.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters